| 18.92 -9.08 (-32.43%) | 08-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 43.01 | 1-year : | 58.36 |
| Resists | First : | 36.82 | Second : | 49.97 |
| Pivot price | 0 | |||
| Supports | First : | 15.56 | Second : | 12.95 |
| MAs | MA(5) : | 28.46  |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 49.97 | Low : | 15.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OBX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 26.75 - 26.97 | 26.97 - 27.11 |
| Low: | 16.75 - 16.91 | 16.91 - 17.02 |
| Close: | 18.69 - 18.96 | 18.96 - 19.14 |
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Wed, 12 Aug 2026
Obsidian Therapeutics (OBX) director details multi-year stock option grants - Stock Titan
Wed, 12 Aug 2026
Obsidian Therapeutics (OBX) CFO Julie Feder reports stock options on 3.0M shares - Stock Titan
Wed, 12 Aug 2026
Obsidian Therapeutics (OBX) director Heidi Hagen reports 517,500 option shares - Stock Titan
Wed, 12 Aug 2026
Obsidian Therapeutics (OBX) files insider report for director Peter Barrett - Stock Titan
Sun, 09 Aug 2026
Obsidian Therapeutics, Inc. (OBX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Sun, 09 Aug 2026
Obsidian Therapeutics, Inc. (OBX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|